Methylacridinium and its Cholinergic Properties

Ondrej Soukup,Jan Proska,Jiri Binder,Jana Zdarova Karasova,Gunnar Tobin,Daniel Jun,Jan Marek,Kamil Musílek,Josef Fusek,Kamil Kuca

DOI: https://doi.org/10.1007/s12640-009-9071-8

IF: 3.9781

2009-06-30

Neurotoxicity Research

Abstract:Abstract10-Methylacridinium iodide (methylacridinium; MA) is an inhibitor of cholinesterases. Inhibitors of acetylcholinesterase (AChE) are used in the treatment of myasthenia gravis, Alzheimer’s disease, and in the prophylaxis of poisoning with organophosphates. Using spectrophotometric Ellman’s method at 436 nm and commercial enzymes we found that MA inhibits AChE by binding with relatively high potency to the peripheral anionic site (IC50 = 1.68 ± 0.14 μM; human recombinant AChE) and equally to its inhibition of butyrylcholinesterase (BuChE; IC50 = 3.54 ± 0.27 μM; BuChE from human serum). MA also inhibits the binding of [3H]N-methylscopolamine to the muscarinic M2 receptor subtype, possibly in an allosteric manner (IC50 = 1.90 μM). Functional effects on both the enzyme and the receptor could be observed in contractile studies on the isolated rat bladder. The ability of MA to cross the blood–brain barrier (log P = −0.32; polar surface area 3.88) provides prerequisites for a potential use of the drug in the treatment of neural disorders.

neurosciences